Search results | elan

Reports

Partnering Agreements with Elan

The Partnering Agreements with Elan report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

Melanoma Partnering

The Melanoma Partnering provides understanding and access to the melanoma partnering deals and agreements entered into by the worlds leading healthcare companies.

Insights

Will Allergan and Forest bid for Elan?

Sources suggest that Allergan and Forest will table rival bids to acquire Elan this week

Biotech rumor mill: Game may not be over for Royalty’ Pharma’s bid for Elan

In the biotech rumor mill: Sources stating that the game may not be over for Royalty’ Pharma’s bid for Elan.

Biotech rumor mill: Forest Laboratories mulls bid for Irish drugmaker Elan

According to the biotech rumor mill Forest Laboratories, a big pharma company, is among a handful of companies interested in bidding for Irish drugmaker Elan, a big biotech company.

Biotech rumour mill: Royalty Pharma drops hostile bid for Elan

Royalty Pharma’s hostile $8 billion bid for Irish drug firm Elan lapsed in the biotech rumour mill on Tuesday when it withdrew an appeal against a ruling by Ireland’s regulator on takeover battles.

Biotech rumour mill: Elan put itself on the market

In the biotech rumour mill, Irish drug firm Elan, a big biotech company, puts itself up for sale.

Elan receives $6.7 billion M&A offer from Royalty Pharma with options to the overall sum of $8 billion

Royalty Pharma has raised its bid for Elan again. With sum m&a value now sitting at $6.7 billion with options bringing the overall deal value to $8 billion.

Elan: what to do when you have $3.25 billion windfall?

The rebuilding of a company from the ground up: Elan’s grand plan

Elan rejects Royalty Pharma acquisition offer

Offer for $11.25 or less per share, substantially undervalues the company according to Elan execs

Royalty Pharma makes acquisition offer to Elan shareholders

Royalty Pharma announces firm acquisition offer to acquire Elan, with a $12 a share proposal

Elan receives $6.5 billion offer from Royalty Pharma

Royalty Pharma makes public its proposal for acquisition of Elan for $6.5 billion, in a twist to recent challenging times for the company

Events

Sorry, your search returned no results.


Deals

MedImmune and Immunocore partner for melanoma combinations

Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100

Pharma giants Pfizer and GSK biopharma partners for melanoma therapy

Pfizer biopharma partners with GSK for phase I/II study of combo melanoma therapy

Perrigo seals deal with Elan company acquisition

Perrigo announced company acquisition of big biotech, Elan  under which Elan will be acquired by a new holding company incorporated in Ireland

Elan big biotech deals Speranza Therapeutics for ELND005 license

Elan has entered biotech deals and decides to divest ELND005 to, Speranza Therapeutics, focused on progressing the development of ELND005 (Scyllo-inositol).

Elan’s senior notes financing placement for $800 million

Elan Corporation announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp intend to offer for financing, subject to market conditions, US$800.0 million in aggregate principal amount of Senior Notes due 2021.

Elan & Theravance enter $1 billion royalty financing deal

Elan has completed life science deals with Theravance for royalties of previous GlaxoSmithKline deals in a $1 billion royalty financing deal.

Elan rejects Royalty Pharma acquisition offer

Offer for $11.25 or less per share, substantially undervalues the company according to Elan execs

Johnson & Johnson biotech deals with Elan for equity repurchase

Johnson & Johnson biotech deals to sell shares in big biotech, Elan, for $11.25 per share as part of a $1 billion stock buyback plan.

Royalty Pharma makes acquisition offer to Elan shareholders

Royalty Pharma announces firm acquisition offer to acquire Elan, with a $12 a share proposal

Elanco announces financing facility for $100 million

Elanco, the animal health division of Eli Lilly, a big pharma company, will enter financing for approximately $100 million USD to purchase a minority equity stake in China Animal Healthcare, one of the leading players in the animal health industry in the People’s Republic of China.